Location History:
- Court St Etienne, BE (2003)
- Brussels, BE (2005)
- Farnham, GB (2002 - 2008)
Company Filing History:
5 out of 75 
1 out of 1 Years Active: 2002-2008
Title: Inventor Martin Friede: Pioneering Advances in Vaccine Technology
Introduction
Martin Friede, an accomplished inventor based in Farnham, GB, has made significant contributions to the field of vaccine development. With a total of six patents to his name, Friede's innovations focus primarily on adjuvant compositions that enhance the efficacy of vaccines. His work is notable for its potential to improve health outcomes through effective immunization strategies.
Latest Patents
Friede's latest patents include pioneering adjuvant compositions suitable for use in vaccines. One of his significant inventions involves adjuvants comprising a saponin and an immunostimulatory oligonucleotide, potentially alongside a carrier. This innovative formulation aims to develop vaccines that combine these adjuvants with antigens to create effective medicaments. In another groundbreaking patent, Friede details a novel adjuvant composition that includes a sterol, such as cholesterol, in combination with a saponin fraction known as QS. This immunostimulating complex represents a first successful attempt to prepare ISCOMs with purified QS, paving the way for the creation of highly immunogenic vaccine formulations. His methods of treating individuals suffering from diseases through the administration of these vaccines highlight the practical applications of his research.
Career Highlights
Throughout his career, Martin Friede has been affiliated with prominent companies in the pharmaceutical and biotechnology sectors, including SmithKline Beecham Biologicals. His work there emphasized the importance of innovation in vaccine technology, which is crucial for combating infectious diseases. Friede’s research has positioned him as a key figure in the ongoing development of advanced medical therapies.
Collaborations
Martin Friede has collaborated with distinguished professionals in his field, including coworkers Nathalie Garcon and Philippe Hermand. These collaborations illustrate the importance of teamwork and shared expertise in the advancement of scientific research, particularly in the complex domain of immunology and vaccine development.
Conclusion
Martin Friede’s contributions to vaccine technology through his patents reflect his dedication to improving public health. His innovative approaches to adjuvant compositions and vaccine formulations are set to significantly impact the medical field. As vaccine development continues to evolve, the insights provided by inventors like Friede are invaluable in the pursuit of more effective treatments for various diseases.